Business
A union would create the world’s third-largest drug maker. The target says the hostile offer is bad for shareholders.
Jan. 27, 2004
The takeover of Aventis by Sanofi-Synthelabo would create the world’s third-largest maker of pharmaceuticals.
April 27, 2004
Sanofi-Aventis makes $18.5-billion cash offer for Genzyme
Aug. 30, 2010
Sanofi-Aventis said U.S. regulators approved a long-acting version of sleep aid Ambien, which loses patent protection next year.
Sept. 7, 2005
Swiss drug maker Novartis will start merger talks with French drug firm Aventis to help it fight off a $54.9-billion hostile bid from Sanofi-Synthelabo, another French drug maker.
April 23, 2004
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis.
Dec. 9, 2006
Science & Medicine
The company releases study results indicating that its Acomplia helps patients control blood sugar and lose weight.
June 13, 2005
Sanofi-Aventis and Bristol-Myers Squibb Co. said they had settled a dispute with generic drug maker Apotex Inc. that could keep patent protection on their multibillion-dollar blood thinner Plavix until 2011.
March 22, 2006
Bristol-Myers and Sanofi-Aventis say they will supply documents related to their failed bid to delay generic competition to Plavix.
April 4, 2007
An antibiotic made by French drug maker Sanofi-Aventis may reduce some symptoms when asthma worsens but it does not improve breathing capacity, according to a study financed by the drug company.
April 17, 2006